Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Choong Ang Vaccine Laboratories Co., Ltd. (072020:KRX), powered by AI.
Choong Ang Vaccine Laboratories Co., Ltd. is currently trading at ₩9,720. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Choong Ang Vaccine Laboratories Co., Ltd. on Alpha Lenz.
Choong Ang Vaccine Laboratories Co., Ltd.'s P/E ratio is 14.9.
“Choong Ang Vaccine Laboratories Co., Ltd. trades at a P/E of 14.9 (undervalued) with modest ROE of 5.9%.”
Ask for details →Choong Ang Vaccine Laboratories Co., Ltd. (CAVAC) is a key player in the biopharmaceutical industry, with a primary focus on the development, production, and distribution of veterinary vaccines. Established in South Korea, the company specializes in biologics for livestock and pets, aiming to enhance animal health and prevent the spread of contagious diseases. CAVAC's extensive product portfolio includes vaccines for poultry, swine, cattle, and companion animals, enabling it to cater to a diverse range of clients, from large-scale farms to individual pet owners. As biosecurity becomes increasingly critical in agriculture, CAVAC's role in supplying effective and innovative veterinary solutions contributes significantly to the food safety and agribusiness sectors. The company's research-driven approach and adherence to rigorous quality standards fortify its market standing, positioning it as a strategic contributor within both local and international markets, where the demand for animal health solutions continues to grow.
“Choong Ang Vaccine Laboratories Co., Ltd. trades at a P/E of 14.9 (undervalued) with modest ROE of 5.9%.”
Ask for details →Choong Ang Vaccine Laboratories Co., Ltd. (ticker: 072020) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 167 employees. Market cap is $91.9B.
The current price is ₩9,720 with a P/E ratio of 14.93x and P/B of 0.87x.
ROE is 5.88% and operating margin is 13.20%. Annual revenue is $49.1B.